Comparative effects of vinblastine and procarbazine in advanced Hodgkin's disease

G. Bonadonna, S. Monfardini, C. Oldini

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

The authors analyze the responses obtained in a group of patients with generalized Hodgkin's disease in which a sequential chemotherapy with vinblastine-procarbazine has been administered. Patients before receiving vinblastine had been treated with radiotherapy and alkylating agents and with vinblastine before treatment with procarbazine. A 55·2% objective improvement for more than 1 month was obtained after treatment with vinblastine in 38 patients and 46·4% after procarbazine in 28 patients. The difference in the response rate is not statistically significant. At the doses administered procarbazine did not produce depression of bone marrow despite prior extensive and prolonged myelosuppressive treatment. The authors conclude that procarbazine even if administered after radiomimetic agents and vinblastine is an effective agent in the treatment of advanced Hodgkin's disease and that the number and the quality of regressions produced by this drug is comparable to those obtained with vinblastine. Sequential vs intensive combination chemotherapy in Hodgkin's disease is also discussed.

Original languageEnglish
Pages (from-to)393-402
Number of pages10
JournalEuropean Journal of Cancer (1965)
Volume5
Issue number4
Publication statusPublished - Sep 1969

Fingerprint

Procarbazine
Vinblastine
Hodgkin Disease
Alkylating Agents
Therapeutics
Combination Drug Therapy
Radiotherapy
Bone Marrow
Drug Therapy
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Comparative effects of vinblastine and procarbazine in advanced Hodgkin's disease. / Bonadonna, G.; Monfardini, S.; Oldini, C.

In: European Journal of Cancer (1965), Vol. 5, No. 4, 09.1969, p. 393-402.

Research output: Contribution to journalArticle

Bonadonna, G, Monfardini, S & Oldini, C 1969, 'Comparative effects of vinblastine and procarbazine in advanced Hodgkin's disease', European Journal of Cancer (1965), vol. 5, no. 4, pp. 393-402.
Bonadonna, G. ; Monfardini, S. ; Oldini, C. / Comparative effects of vinblastine and procarbazine in advanced Hodgkin's disease. In: European Journal of Cancer (1965). 1969 ; Vol. 5, No. 4. pp. 393-402.
@article{8634810e01614b36abb49fbb1e1e64d2,
title = "Comparative effects of vinblastine and procarbazine in advanced Hodgkin's disease",
abstract = "The authors analyze the responses obtained in a group of patients with generalized Hodgkin's disease in which a sequential chemotherapy with vinblastine-procarbazine has been administered. Patients before receiving vinblastine had been treated with radiotherapy and alkylating agents and with vinblastine before treatment with procarbazine. A 55·2{\%} objective improvement for more than 1 month was obtained after treatment with vinblastine in 38 patients and 46·4{\%} after procarbazine in 28 patients. The difference in the response rate is not statistically significant. At the doses administered procarbazine did not produce depression of bone marrow despite prior extensive and prolonged myelosuppressive treatment. The authors conclude that procarbazine even if administered after radiomimetic agents and vinblastine is an effective agent in the treatment of advanced Hodgkin's disease and that the number and the quality of regressions produced by this drug is comparable to those obtained with vinblastine. Sequential vs intensive combination chemotherapy in Hodgkin's disease is also discussed.",
author = "G. Bonadonna and S. Monfardini and C. Oldini",
year = "1969",
month = "9",
language = "English",
volume = "5",
pages = "393--402",
journal = "European Journal of Cancer",
issn = "0014-2964",
publisher = "Elsevier Ltd",
number = "4",

}

TY - JOUR

T1 - Comparative effects of vinblastine and procarbazine in advanced Hodgkin's disease

AU - Bonadonna, G.

AU - Monfardini, S.

AU - Oldini, C.

PY - 1969/9

Y1 - 1969/9

N2 - The authors analyze the responses obtained in a group of patients with generalized Hodgkin's disease in which a sequential chemotherapy with vinblastine-procarbazine has been administered. Patients before receiving vinblastine had been treated with radiotherapy and alkylating agents and with vinblastine before treatment with procarbazine. A 55·2% objective improvement for more than 1 month was obtained after treatment with vinblastine in 38 patients and 46·4% after procarbazine in 28 patients. The difference in the response rate is not statistically significant. At the doses administered procarbazine did not produce depression of bone marrow despite prior extensive and prolonged myelosuppressive treatment. The authors conclude that procarbazine even if administered after radiomimetic agents and vinblastine is an effective agent in the treatment of advanced Hodgkin's disease and that the number and the quality of regressions produced by this drug is comparable to those obtained with vinblastine. Sequential vs intensive combination chemotherapy in Hodgkin's disease is also discussed.

AB - The authors analyze the responses obtained in a group of patients with generalized Hodgkin's disease in which a sequential chemotherapy with vinblastine-procarbazine has been administered. Patients before receiving vinblastine had been treated with radiotherapy and alkylating agents and with vinblastine before treatment with procarbazine. A 55·2% objective improvement for more than 1 month was obtained after treatment with vinblastine in 38 patients and 46·4% after procarbazine in 28 patients. The difference in the response rate is not statistically significant. At the doses administered procarbazine did not produce depression of bone marrow despite prior extensive and prolonged myelosuppressive treatment. The authors conclude that procarbazine even if administered after radiomimetic agents and vinblastine is an effective agent in the treatment of advanced Hodgkin's disease and that the number and the quality of regressions produced by this drug is comparable to those obtained with vinblastine. Sequential vs intensive combination chemotherapy in Hodgkin's disease is also discussed.

UR - http://www.scopus.com/inward/record.url?scp=0014572758&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0014572758&partnerID=8YFLogxK

M3 - Article

C2 - 4899673

AN - SCOPUS:0014572758

VL - 5

SP - 393

EP - 402

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0014-2964

IS - 4

ER -